From: Iron replacement therapy in heart failure: a literature review
Guideline group | Year of publication | Recommendation | Class/level of evidence |
---|---|---|---|
European Society of Cardiology [44] | 2016 | IV ferrous carboxymaltose should be considered in symptomatic patients with HFrEF and ID (ferritin < 100 µg/L, or ferritin 100–299 if TSAT < 20%) | IIa (weight of evidence is in favour of usefulness)/level A |
American Heart Association/American College of Cardiology [47] | 2016 | In HF patients with NYHA class II and III and ID (ferritin < 100 ng/mL, or 100–300 ng/mL if TSAT < 20%), IV iron may be reasonable to improve functional status and quality of life | IIb (weak strength of recommendation)/ level B-R |
Scottish Intercollegiate Guidelines Network [46] | 2017 | HFrEF patients with either NYHA class III and LVEF ≤ 45%; or NYHA class II and LVEF ≤ 40%, along with haemoglobin 9.5–13.5 g/dL should be considered for IV iron | 1+ + + (high-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias) |
National Institute for Health and Care Excellence [48] | 2018 | No recommendation | Â |